title: Effects of gamma-decanolactone on seizures induced by PTZ-kindling in mice.
abstract: Gamma-decanolactone is a monoterpene compound, and its psychopharmacological evaluation in mice revealed that it has a dose-dependent effect on the central nervous system, with hypnotic, anticonvulsant, and hypothermic activity. The aim of the present study was to investigate the effect of gamma-decanolactone on pentylenetetrazole (PTZ)-kindling in mice. Phenobarbital, an antiepileptic drug, was also tested for the purpose of comparison. After the behavioral procedures had been undertaken, the animals were killed and brain tissue was sampled to evaluate DNA damage in the brain using comet assay. The data reported here suggest that the administration of phenobarbital (10 mg/kg) and gamma-decanolactone at 0.3 g/kg, but not at 0.1 g/kg, impairs both the severity and the progression of seizures in the PTZ-kindling model. DNA damage to brain tissue decreased in gamma-decanolactone-treated kindling animals (similar to phenobarbital) as compared to nontreated animals. The results suggest that gamma-decanolactone has dose-dependent anticonvulsant properties, and may also have antiepileptogenic and neuroprotective effects in the PTZ-kindling model.
authors.affiliation: Curso de Pós-Graduação em Genética e Toxicologia Aplicada, Laboratório de Farmacologia e Laboratório de Genética Toxicológica, Universidade Luterana do Brasil, Av. Farroupilha 8001, Bairro São José, Canoas, RS 92425-900, Brasil.
authors.forename: Paulo Alexandre
authors.initials: PA
authors.lastname: de Oliveira
authors.forename: Felipe Luis
authors.initials: FL
authors.lastname: Lino
authors.forename: Shandale Emanuele
authors.initials: SE
authors.lastname: Cappelari
authors.forename: Lucimar Filot
authors.initials: LF
authors.lastname: da Silva Brum
authors.forename: Jaqueline Nascimento
authors.initials: JN
authors.lastname: Picada
authors.forename: Patrícia
authors.initials: P
authors.lastname: Pereira
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology* / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects* / Q000503:physiopathology; D020552:Comet Assay; D003292:Convulsants / Q000037:antagonists & inhibitors; D004249:DNA Damage / Q000187:drug effects / Q000235:genetics; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004827:Epilepsy / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D007696:Kindling, Neurologic / Q000187:drug effects* / Q000502:physiology; D007783:Lactones / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D051379:Mice; D009410:Nerve Degeneration / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control; D010433:Pentylenetetrazole / Q000037:antagonists & inhibitors*; D010634:Phenobarbital / Q000037:antagonists & inhibitors; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants; D003292:Convulsants; D007783:Lactones; C109757:decan-4-olide; D010433:Pentylenetetrazole; D010634:Phenobarbital